CD40 and neoplasm: For conventional cell therapy, the antitumor efficacy of a combination of tumor-targeted antimesothelin CAR-T cells and M2 inhibitors has been confirmed and TAM-associated cell therapy based on specific markers, such as CD40, is being studied [218].